Cellectar Biosciences, Inc. (CLRB) stock
CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.92−0.09 (-8.88%)
Close on Nov 17, 2026Market cap $8.70MP/E –Yield –
Cellectar Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Cellectar Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$19.47M. For fiscal 2025 it was -$23.12M. The highest annual figure on record is -$3.38M in fiscal 2010.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.12M | – |
| FY2024 | Dec 31, 2024 | -$47.58M | – |
| FY2023 | Dec 31, 2023 | -$32.38M | – |
| FY2022 | Dec 31, 2022 | -$25.22M | – |
| FY2021 | Dec 31, 2021 | -$22.57M | – |
| FY2020 | Dec 31, 2020 | -$13.93M | – |
| FY2019 | Dec 31, 2019 | -$11.69M | – |
| FY2018 | Dec 31, 2018 | -$11.44M | – |
| FY2017 | Dec 31, 2017 | -$11.02M | – |
| FY2016 | Dec 31, 2016 | -$8.28M | – |
| FY2015 | Dec 31, 2015 | -$8.21M | – |
| FY2014 | Dec 31, 2014 | -$8.84M | – |
| FY2013 | Dec 31, 2013 | -$9.15M | – |
| FY2012 | Dec 31, 2012 | -$6.59M | – |
| FY2011 | Dec 31, 2011 | -$5.97M | – |
| FY2010 | Dec 31, 2010 | -$3.38M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.85M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.34M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.12M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.38M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.91M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.07M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.53M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.41M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.01M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.51M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.43M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.88M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.75M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.87M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.05M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.51M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.68M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.54M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.65M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.82M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.74M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.97M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.55M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.18M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.54M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.66M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.99M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.35M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.21M | – |
See a number that looks wrong?